Oruka Therapeutics (ORKA) Stock Forecast & Price Target

$25.38

-1.09 (-4.12%)

(As of 09/18/2024 ET)

Oruka Therapeutics - Analysts' Recommendations and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Buy
Based on 6 Analyst Ratings

Based on 6 Wall Street analysts who have issued ratings for Oruka Therapeutics in the last 12 months, the stock has a consensus rating of "Buy." Out of the 6 analysts, 4 have given a buy rating, and 2 have given a strong buy rating for ORKA.

Consensus Price Target

$41.25
62.53% Upside

High Forecast	$44.00
Average Forecast	$41.25
Low Forecast	$40.00

According to the 6 analysts' twelve-month price targets for Oruka Therapeutics, the average price target is $41.25. The highest price target for ORKA is $44.00, while the lowest price target for ORKA is $40.00. The average price target represents a forecasted upside of 62.53% from the current price of $25.38.

Type	Current Forecast 9/19/23 to 9/18/24	1 Month Ago 8/20/23 to 8/19/24	3 Months Ago 6/21/23 to 6/20/24	1 Year Ago 9/19/22 to 9/19/23
Consensus Rating	Buy	N/A	N/A	N/A
Strong Buy	2 Strong Buy rating(s)	N/A	N/A	N/A
Buy	4 Buy rating(s)	N/A	N/A	N/A
Hold	0 Hold rating(s)	N/A	N/A	N/A
Sell	0 Sell rating(s)	N/A	N/A	N/A
Consensus Price Target	$41.25	N/A	N/A	N/A
Forecasted Upside	62.53% Upside	N/A	N/A	N/A

Get Oruka Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ORKA and its competitors with MarketBeat's FREE daily newsletter.

Central Bank Abandons USD (Ad)

Startling new evidence shows the U.S. Central Bank is abandoning the currency we’ve relied on for centuries – the United States Dollar… And placing a ‘quiet bet’ on a new type of currency… Gold.

Click here now to get your free 'Protect Your Wealth' Guide.

ORKA Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

ORKA Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Oruka Therapeutics Stock vs. The Competition

Type	Oruka Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	3.33	2.77	2.50
Consensus Rating	Buy	Moderate Buy	Moderate Buy
Predicted Upside	58.23% Upside	1,008.10% Upside	7.49% Upside
News Sentiment Rating	Neutral News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
9/17/2024	Leerink Partnrs 0 of 5 stars	D. Risinger Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
9/17/2024	Leerink Partners 1 of 5 stars		Initiated Coverage	Outperform	$44.00	+69.88%
9/16/2024	Lifesci Capital 2 of 5 stars	S. Slutsky Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$41.00	+61.04%
9/16/2024	TD Cowen Subscribe to MarketBeat All Access for the recommendation accuracy rating	T. Van. Buren Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy
9/13/2024	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$40.00	+53.85%
9/4/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$40.00	+400,000,000.00%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Wednesday at 09:50 PM ET.

ORKA Forecast - Frequently Asked Questions

What is Oruka Therapeutics' forecast for 2024?: According to the research reports of 6 Wall Street equities research analysts, the average twelve-month stock price forecast for Oruka Therapeutics is $41.25, with a high forecast of $44.00 and a low forecast of $40.00.
Should I buy or sell Oruka Therapeutics stock right now?: 6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oruka Therapeutics in the last year. There are currently 4 buy ratings and 2 strong buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ORKA shares.
Does Oruka Therapeutics's stock price have much upside?: According to analysts, Oruka Therapeutics's stock has a predicted upside of 59.97% based on their 12-month stock forecasts.
Has Oruka Therapeutics been upgraded by Wall Street analysts recently?: Over the previous 90 days, Oruka Therapeutics's stock had 2 upgrades by analysts.
What analysts cover Oruka Therapeutics?: Oruka Therapeutics has been rated by research analysts at Jefferies Financial Group, Leerink Partners, Leerink Partnrs, Lifesci Capital, TD Cowen, and Wedbush in the past 90 days.
Do Wall Street analysts like Oruka Therapeutics more than its competitors?: Analysts like Oruka Therapeutics more than other "medical" companies. The consensus rating for Oruka Therapeutics is Buy while the average consensus rating for "medical" companies is Moderate Buy. Learn more on how ORKA compares to other companies.